Can-Fite BioPharma Ltd. (CANF)
NYSEAMERICAN: CANF · Real-Time Price · USD
4.550
-0.050 (-1.09%)
Mar 6, 2026, 4:00 PM EST - Market closed
Can-Fite BioPharma Employees
Can-Fite BioPharma had 5 employees as of December 31, 2024. The number of employees decreased by 3 or -37.50% compared to the previous year.
Employees
5
Change (1Y)
-3
Growth (1Y)
-37.50%
Revenue / Employee
$112,000
Profits / Employee
-$1,759,800
Market Cap
6.38M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Aptevo Therapeutics | 37 |
| Theriva Biologics | 22 |
| Processa Pharmaceuticals | 10 |
| XTL Biopharmaceuticals | 10 |
| Purple Biotech | 9 |
| Aprea Therapeutics | 8 |
| Immuron | 7 |
| Mustang Bio | 6 |
CANF News
- 3 days ago - Can-Fite's Namodenoson Hits Phase 2a Goal; Raises $4M Via Warrants - Nasdaq
- 3 days ago - Micro-Cap Can-Fite BioPharma Shares Surge On Successful Pancreatic Cancer Drug Study - Benzinga
- 3 days ago - Micro-Cap Can-Fite BioPharma Shares Surge On Successful Pancreatic Cancer Drug Study - Benzinga
- 3 days ago - Can-Fite BioPharma (CANF) Achieves Positive Results in Pancreatic Cancer Study - GuruFocus
- 3 days ago - Can-Fite's Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study - GlobeNewsWire
- 18 days ago - Can-Fite BioPharma (CANF) Unveils Promising Obesity Study Results - GuruFocus
- 26 days ago - Can-Fite (CANF) Gains Canadian Patent for Anti-Obesity Drug Namodenoson - GuruFocus
- 4 weeks ago - Can-Fite BioPharma (CANF) Treatment Aids Successful Liver Transplant - GuruFocus